对子宫内膜癌的内分泌疗法:当前的证据,抵抗机制和生物标志物驱动的患者选择
Taro Yamanaka1, Hiroshi Yoshida2, Tatsunori Shimoi1
1Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Current oncology (Toronto, Ont.)
|February 26, 2026
概括
子宫内膜癌的治疗正在转向精准医学. 新型组合内分泌疗法,包括向药物,有望改善结果,特别是在特定的分子子组中.
科学领域:
- 妇科瘤学 妇科瘤学
- 精准医学是一门精准的医学.
- 分子病理学分子病理学
背景情况:
- 子宫内膜癌 (EC) 治疗正在从传统的组织学发展到分子分类 (癌症基因组图谱 - TCGA).
- "没有特定分子形状" (NSMP) 亚组占EC病例的很大一部分,是内分泌疗法 (ET) 的关键目标.
- 虽然ET已确立,但其单一疗法的有效性有限,需要探索新的策略.
研究的目的:
- 审查对子宫内膜癌的现有和新兴内分泌策略.
- 突出结合疗法和向药物的作用,以克服ET耐药性.
- 讨论分子生物标志物在精密瘤学患者选择中的重要性.
主要方法:
- 关于内分泌疗法和EC的分子分类的综合文献综述.
- 对联合疗法 (例如CDK4/6,mTOR抑制剂) 的最近临床试验数据的分析.
- 预测生物标志物和下一代药物,如选择性雌激素受体降解剂 (SERDs) 的讨论.
主要成果:
- 集成分子向药物的组合疗法显著改善了EC的临床结果.
- 患有TP53野生型和CTNNB1突变的患者对这些新的组合表现出了显著的反应.
- 下一代SERD和精细的生物标志物策略有可能提高患者选择.
结论:
- 内分泌疗法正在转变为高级或复发性EC的精密瘤学的基石.
- 分子洞察力正在推动个性化治疗方法,超越传统的息作用.
- 基于内分泌的组合策略为EC提供了更有效和个性化的治疗范式.
关键词:
这是一种CDK4/6抑制剂.内分泌疗法是一种内分泌疗法.这是子宫内膜癌的癌症.雌激素受体的受体是雌激素受体.这是一种mTOR抑制剂.孕激素受体的受体是什么 孕激素受体孕激素 (progestin) 是一种孕激素.选择性的雌激素受体降解剂更多相关视频
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
13.6K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.3K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
